Investigator Sponsored Trial Opportunities

Summit Therapeutics (“Summit”) may provide support for independent research such as Investigator Sponsored Trials (“ISTs”) that advance medical and scientific knowledge about Summit products, related therapeutic areas, or disease state areas of interest.

An IST is a study that is designed, implemented, and sponsored by an investigator / entity / group who has requested monetary funding and / or Summit materials (e.g., drug) to support the execution of a research study. ISTs include a variety of clinical studies such as interventional and non-interventional studies, as well as prospective or retrospective studies. Other types of studies that may be considered an IST include non-clinical (animal), in-vitro and in-vivo studies. Summit may not serve as the sponsor of an IST.

Qualified researchers / investigators are requested to submit their proposals according to the instructions found on this page. Proposals are reviewed by a cross-functional Summit Scientific Review Committee that meets periodically. Summit’s decision to support a proposal will be based on its research merit and alignment with our Areas of Scientific Interest. Furthermore, Summit will also consider the expertise of the proposed sponsor, including their experience in the relevant therapeutic area, demonstrated ability to successfully conduct clinical trials, and available resources.

Summit does not provide operational support (e.g., authorship of a protocol, statistical analysis, study report, publication, site monitoring) for ISTs. Operational support for ISTs is the responsibility of the sponsor. 

Please be aware that funding is limited, and submission of an application (even one that meets stated criteria) does not guarantee that funding will be granted to your organization. Summit receives many applications for support and cannot support them all.

Areas of Scientific Interest​

We welcome unsolicited research proposals from qualified investigators in our strategic areas of interest which we list below. Well-thought through studies that enhance our delivery of our innovative therapy, ivonescimab, to more patients worldwide, enhance patient care, and align with our strategic areas of interest will be considered. If there is an area of interest not listed here that you are interested in pursuing with ivonescimab, please reach out to us and we are happy to discuss further.

  • Bladder Cancer
  • Gastric Cancer
  • Non-small Cell Lung Cancer (NSCLC)
    • Novel Combinations (i.e., Antibody-drug conjugates etc.)
    • Specific Populations (i.e., Unfit etc.)
  • Ovarian Cancer
  • Renal Cell Carcinoma​

Summit Therapeutics is currently accepting IST applications through May 1, 2024. If you are interested in submitting an IST proposal, please contact your local MSL or email us at for further instructions.

IST Request Process​

To submit an IST proposal, please contact your local MSL or email us at for further instructions. A completed IST application form and the investigator’s curriculum vitae (CV) is required for consideration by Summit’s Scientific Review Committee.  

Submission of a proposal requesting Summit’s support (e.g., funding and / or drug supply) is not a guarantee of acceptance or approval of that proposal. A formal notification regarding the status of your application will be communicated once a decision is reached. For any questions, email us at